已出刊文章

【綜合評述】腎臟移植後非典型溶血性尿毒症候群之補體抑制治療與藥事照護:文獻回顧與臨床實務建議
Complement Inhibition and Pharmacist-Led Care in Post-Transplant Atypical Hemolytic Uremic Syndrome: A Review of Evidence and Clinical Practice Considerations
非典型溶血性尿毒症候群、腎臟移植、補體抑制劑、血栓性微血管病變、藥事照護、atypical hemolytic uremic syndrome, kidney transplantation, complement inhibitors, thrombotic microangiopathy, clinical pharmaceutical care
鄭景耀 Ching-Yao Cheng1 、劉兆鴻 Jaw-Horng Liou1 、陳秀美 Hsiu-Mei Chen1 、王慧瑜 Hue-Yu Wang2,*
1臺中榮民總醫院藥學部 、2台南市立安南醫院藥劑科──委託中國醫藥大學興建經營

摘要
非典型溶血性尿毒症候群(atypical hemolytic uremic syndrome, aHUS) 為由補體替代途徑失衡所致之超罕見血栓性微血管病變,盛行率約每百萬人口4–5例,未治療者超過50%於一年內進展至末期腎臟病或死亡。腎臟移植病人因先天補體異常與移植相關觸發因素並存,為極高風險族群,移植後aHUS發生率約3%–4%,高風險基因型復發率可達60%–85%,若延誤治療,移植腎失功風險高達80%–90%,並可伴隨20%–70%腎外器官受損。補體抑制劑(如eculizumab、ravulizumab)已成為主要治療,能顯著改善腎功能與移植腎存活率。本文整合最新證據,探討移植後aHUS之病理機轉、臨床辨識、基因風險分層、補體抑制治療,並評估救援式治療相較常規預防性治療之成本效益。藥師於感染預防、補體抑制劑監測、免疫抑制劑調整與用藥成本管理,以及在降低移植後aHUS風險中扮演重要角色,有助提升病人與移植腎長期預後,提升病人安全與醫療品質。
 
ABSTRACT
Atypical hemolytic uremic syndrome (aHUS) is characterized as an ultra-rare, complement-mediated thrombotic microangiopathy caused by dysregulation of the alternative complement pathway, with an estimated prevalence of 4–5 cases per million individuals. Without timely therapy, more than 50% of patients progress to end-stage kidney disease or death within one year. Kidney transplant recipients represent a particularly high-risk population due to underlying complement abnormalities combined with transplant-related triggers. Post-transplant aHUS occurs in approximately 3%–4% of recipients, and recurrence rates reach 60%–85% among those with high-risk complement genetic variants. Delayed diagnosis and intervention are associated with graft failure rates as high as 80%–90%, along with extra-renal involvement in 20%–70% of cases. Complement inhibitors such as eculizumab and ravulizumab serve as the mainstay of therapy and significantly improve kidney function and graft survival. This review summarizes available evidence on disease mechanisms, clinical recognition, genetic risk stratification, and complement-blocking strategies in the post-transplant setting, and also highlights that rescue therapy demonstrates potential cost-effectiveness advantages compared with routine prophylaxis. Pharmacists play a critical role in infection prevention, complement inhibitor monitoring, immunosuppressant optimization, and pharmacoeconomic stewardship, thereby reducing post-transplant aHUS risk, enhancing graft and patient outcomes, and improving overall safety and care quality.

Submitted for publication: 2025.12.29; Accepted for publication: 2026.04.14

操作進行中,請稍候~~~~
×
加载中...

系統通知

不再顯示此通知
×